Tag Archives: PF-02341066

Gender distinct drug metabolic process of PF-02341066 in rats–role of sulfoconjugation

Zhong WZ, Zhan J, Kang P, Yamazaki S “Current drug metabolic rate 2010, 11″ PF-02341066 is actually a selective c-Met/Alk tyrosine kinase inhibitor at present in clinical advancement as an anticancer agent. Non-clinical toxicokinetic evaluation in rats uncovered gender-related variations … Continue reading

Posted in Uncategorized | Tagged | Leave a comment